Turn Biotechnologies completes latest round of funding
Summary
MOUNTAIN VIEW, Calif., April 28, 2021 /PRNewswire/ -- Turn Biotechnologies, a company developing novel RNA medicines for untreatable age-related conditions, today announced that it has closed its latest round of funding. "These investments by funds with a reputation for picking winners around the world recognize Turns innovation, vision and potential to disrupt the market," said CEO Anja Krammer. Our new investors enable Turn to bring to the market the promise of a technology that has the potential to improve quality of life and change healthcare economics globally. The companys proprietary mRNA technology combats the effects of aging in the epigenome, thus restoring optimal gene expression and enabling cells to function as vigorously as when they were younger. The firm was founded by Vinod Khosla, co-founder of Sun Microsystems, and focuses on transformative technology in consumer, enterprise, education, financial services, health, big data, agriculture/food, sustainable energy and robotics.